Literature DB >> 23271489

The influence of surgical factors on persisting symptoms 3 years after esophageal cancer surgery: a population-based study in Sweden.

Maartje van der Schaaf1, Martin Rutegård, Pernilla Lagergren.   

Abstract

BACKGROUND: Little is known about the long-term effects of surgical approach and type of anastomosis in the surgical treatment of esophageal cancer on patient-reported outcomes.
METHODS: A Swedish nationwide, population-based cohort study included patients undergoing esophagectomy for esophageal cancer in 2001-2005. The predefined exposures included surgical approach (transhiatal or transthoracic) and anastomotic technique (hand-sewn or mechanical). The outcomes were esophageal-specific symptoms 3 years after the surgery. Symptoms were measured using the cancer-specific quality of life questionnaire, the QLQ-C30, supplemented by an esophageal cancer-specific module (QLQ-OES18), both developed by the European Organisation for Research and Treatment of Cancer. Logistic regression models were used to estimate relative risk, expressed as odds ratios (OR) with 95 % confidence intervals (CI), of experiencing symptoms as assessed by the questionnaires.
RESULTS: Among the 178 included patients, there was an 84 % participation rate. No statistically significant differences were found regarding surgical approach. However, point estimates indicate that patients operated on with a transhiatal approach had a lower risk for symptoms of nausea and vomiting (OR = 0.5, 95 % CI 0.1-1.9), diarrhea (OR = 0.5, 95 % CI 0.2-1.8), and trouble swallowing (OR = 0.4, 95 % CI 0-3), and a slightly higher risk for loss of appetite (OR = 2, 95 % CI 0.7-5.6) compared with patients operated on with a transthoracic approach. Anastomotic technique did not seem to influence the risk for any of the selected symptoms.
CONCLUSIONS: Surgical approach and type of anastomosis do not seem to influence the risk of general and esophageal-specific cancer symptoms 3 years after surgery for esophageal cancer.

Entities:  

Mesh:

Year:  2012        PMID: 23271489     DOI: 10.1245/s10434-012-2690-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  Eating Behaviors of Postoperative Esophageal Cancer Patients During the First Year After Surgery.

Authors:  Yukina Ueda; Masami Chujo
Journal:  Yonago Acta Med       Date:  2020-08-20       Impact factor: 1.641

2.  Profiling patient-reported symptom recovery from oesophagectomy for patients with oesophageal squamous cell carcinoma: a real-world longitudinal study.

Authors:  Xi Luo; Qin Xie; Qiuling Shi; Yan Miao; Qingsong Yu; Hongfan Yu; Hong Yin; Xuefeng Leng; Yongtao Han; Hong Zhou
Journal:  Support Care Cancer       Date:  2021-11-24       Impact factor: 3.603

Review 3.  Oesophageal cancer.

Authors:  Elizabeth C Smyth; Jesper Lagergren; Rebecca C Fitzgerald; Florian Lordick; Manish A Shah; Pernilla Lagergren; David Cunningham
Journal:  Nat Rev Dis Primers       Date:  2017-07-27       Impact factor: 52.329

4.  Long-Term Quality of Life Following Transthoracic and Transhiatal Esophagectomy for Esophageal Cancer.

Authors:  E Jezerskyte; L M Saadeh; E R C Hagens; M A G Sprangers; L Noteboom; H W M van Laarhoven; W J Eshuis; M C C M Hulshof; M I van Berge Henegouwen; S S Gisbertz
Journal:  J Gastrointest Surg       Date:  2020-09-09       Impact factor: 3.452

5.  The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer.

Authors:  Alexandra D Dreyfuss; Andrew R Barsky; E Paul Wileyto; Jennifer R Eads; John C Kucharczuk; Noel N Williams; Thomas B Karasic; James M Metz; Edgar Ben-Josef; John P Plastaras; Andrzej P Wojcieszynski
Journal:  Cancer Med       Date:  2021-01-20       Impact factor: 4.452

6.  Early complications following oesophagectomy for cancer in relation to long-term healthcare utilisation: a prospective population-based cohort study.

Authors:  Eva Doorakkers; Peter Konings; Fredrik Mattsson; Jesper Lagergren; Nele Brusselaers
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.